{
  "abstract": "Engineered T cells transiently expressing tumor-targeting receptors are an attractive form of engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term adverse side-effects. However, multiple rounds of treatment are often required, increasing patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of transient engineered T cells by screening a panel of small molecules targeting epigenetic regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells targetting hepatocellular carcinoma, we find that short-term inhibition of G9a/GLP increases T cell antitumor activity in in vitro models and an orthotopic mouse model. G9a/GLP inhibition increases granzyme expression without terminal T cell differentiation or exhaustion and results in specific changes in expression of genes and proteins involved in pro-inflammatory pathways, T cell activation and cytotoxicity.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "name": "Maxine S. Y. Lam"
    },
    {
      "name": "Jose Antonio Reales-Calderon"
    },
    {
      "name": "Jin Rong Ow"
    },
    {
      "name": "Joey J. Y. Aw"
    },
    {
      "name": "Damien Tan"
    },
    {
      "name": "Ragavi Vijayakumar"
    },
    {
      "name": "Erica Ceccarello"
    },
    {
      "name": "Tommaso Tabaglio"
    },
    {
      "name": "Yan Ting Lim"
    },
    {
      "name": "Wang Loo Chien"
    },
    {
      "name": "Fritz Lai"
    },
    {
      "name": "Anthony Tan Tanoto"
    },
    {
      "name": "Qingfeng Chen"
    },
    {
      "name": "Radoslaw M. Sobota"
    },
    {
      "name": "Giulia Adriani"
    },
    {
      "name": "Antonio Bertoletti"
    },
    {
      "name": "Ernesto Guccione"
    },
    {
      "name": "Andrea Pavesi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/aqzbm469rw8a5.bib",
  "cited_by": 26,
  "doi": "10.1038/s41467-023-36160-5",
  "fulltext_url": null,
  "id": "aqzbm469rw8a5",
  "issns": [
    "2041-1723",
    "2041-1723"
  ],
  "landing_url": "https://hal.science/hal-05776437v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.imm"
    ],
    [
      "hal",
      "2.sdv.imm.imm"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W4318985148",
  "pdf_url": "https://www.nature.com/articles/s41467-023-36160-5.pdf",
  "pmcid": null,
  "pmid": "36732506",
  "published": "2026-10-03",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/aqzbm469rw8a5.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:46Z",
      "native_id": "hal-05776437",
      "source": "hal",
      "url": "https://hal.science/hal-05776437v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.imm",
      "subfield": "immunology"
    }
  ],
  "title": "G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma",
  "title_text": "G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:46Z",
  "url": "https://research.draconitic.com/paper/aqzbm469rw8a5",
  "venue": "Nature Communications",
  "versions": []
}